Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Acetic Acid | HCID 176 | — |
| Reactant | HCID 57565333 | HCID 57565333 | — |
| Reactant | HCID 59410475 | HCID 59410475 | — |
| Reactant | HCID 178419192 | HCID 178419192 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 59410458 | HCID 59410458 | — |
Reaction Steps
5-(3,4-dihydro-2-oxo-2H-benzo[e][1,3]oxazin-6-yl)-2H-1,2,3-triazole-4-carbaldehyde (15 mg, 0.06 mmol) and (R)-1-(5-(trifluoromethyl)pyridin-2-yl)-2-methylpiperazine (20 mg, 0.08 mmol) are mixed in DMF (1 ml) followed by addition of acetic acid (AcOH) (30 ul). The mixture is stirred at room temperature for 30 minute and then sodium triacetate boron hydride (42 mg, 0.2 mmol) is added. The resulting suspension is then stirred at room temperature overnight. The reaction is quenched using an aqueous saturated solution of sodium bicarbonate and then extracted with ethyl acetate (10 ml×4). The combined organic phase is concentrated and the resulting crude product is purified by HPLC giving 6-(5-(((R)-4-(5-(trifluoromethyl)pyridin-2-yl)-3-methylpiperazin-1-yl)methyl)-2H-1,2,3-triazol-4-yl)-3,4-dihydrobenzo[e][1,3]oxazin-2-one as a white powder. m/e:474 (M+1).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08178526B2 |
|---|
| Source dataset | uspto-grants-2012_05 |
|---|
| ORD ID | ord-680816dfde4047258be05c6ce624113d |
|---|
| Source note | uspto-grants-2012_05 |
|---|